外周血USP1基因甲基化与大肠癌预后风险的关系

doi:10.11904/j.issn.1002-3070.2019.05.007

摘要/Abstract

摘要： 目的探讨外周血中去泛素化酶USP1甲基化及临床特征与大肠癌预后风险的关系。方法采用队列研究,共纳入286例大肠癌患者。使用高分辨率熔解曲线分析法(HRM)检测基因甲基化水平。应用Cox回归模型评估基因甲基化及临床特征与大肠癌预后风险之间的关联。结果在男性大肠癌病例中,USP1甲基化增加预后不良风险(HR=2.091,95% CI:1.195~3.661,P=0.010)。临床病理特征中,UICC肿瘤分期4期(HR=2.464,95% CI:1.205~5.039,P=0.014)、肿瘤大小超过50mm(HR=1.610,95% CI:1.016~2.550,P=0.043)和组织学非腺型(HR=5.117,95% CI:1.142~22.930,P=0.033)是大肠癌不良预后风险增加的影响因素。结论 UICC肿瘤分期4期、肿瘤大小超过50mm和组织学分型为非腺型会增加大肠癌不良预后风险。外周血USP1基因启动子区甲基化与男性大肠癌预后不良风险增加有关。

关键词: 大肠癌, DNA甲基化, USP1

Abstract: Objective The objective of this study was to investigate the relationship between the methylation and clinical features of deubiquitinating enzyme USP1 in peripheral blood and the prognosis risk of colorectal cancer.Methods A total of 286 patients with colorectal cancer were enrolled in the cohort study.The level of DNA methylation status of USP1 was detected using high resolution melting curve analysis(HRM).The Cox regression model was used to assess the association between USP1 methylation and clinical features and prognosis risk of colorectal cancer.Results In male colorectal cancer cases,USP1 methylation could incerease the risk of colorectal cancer with poor pregnosis(HR=2.091,95% CI:1.195~3.661,P=0.010).Among the clinicopathological features,UICC tumor stage 4(HR=2.464,95% CI:1.205~5.039,P=0.014),tumor size over 50 mm(HR=1.610,95% CI:1.016~2.550,P=0.043)and histological non-adenotype(HR=5.117,95% CI:1.142~22.930,P=0.033)were contributing factors to the increased risk of colorectal cancer with poor pregnosis.Conclusion UICC tumor stage 4,tumor size over 50 mm and histological non-adenotype will increase the risk of colorectal cancer with poor pregnosis.The methylation of promoter region of USP1 gene in peripheral blood is associated with an increased risk of poor pregnosis in male colorectal cancer.

Key words: Colorectal cancer(CRC), DNA methylation, USP1

中图分类号:

R735.3+4

张谊微, 石晶, 刘宇鹏, 曹丽明, 胡付兰, 赵亚双. 外周血USP1基因甲基化与大肠癌预后风险的关系[J]. 实用肿瘤学杂志, 2019, 33(5): 420-424.

ZHANG Yiwei, SHI Jing, LIU Yupeng, CAO Liming, HU Fulan, ZHAO Yashuang. Relationship between methylation of USP1 gene in peripheral blood and prognosis risk of colorectal cancer[J]. Journal of Practical Oncology, 2019, 33(5): 420-424.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2019.05.007

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2019/V33/I5/420

参考文献

1 Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
2 Arnold M,Sierra MS,Laversanne M,et al.Global patterns and trends in colorectal cancer incidence and mortality[J].Gut,2017,66(4):683-691.
3 Zhou S,Xiong M,Dai G,et al.MicroRNA-192-5p suppresses the initiation and progression of osteosarcoma by targeting USP1[J].Oncol Lett,2018,15(5):6947-6956.
4 Garcia-Santisteban I,Peters GJ,Giovannetti E,et al.USP1 deubiquitinase:cellular functions,regulatory mechanisms and emerging potential as target in cancer therapy[J].Mol Cancer,2013,12:91.
5 Ma,A,Tang M,Zhang,L,et al.USP1 inhibition destabilizes KPNA2 and suppresses breast cancer metastasis[J].Oncogene,2019,38(13):2405-2419.
6 Ellinger J,Muller SC,Dietrich D.Epigenetic biomarkers in the blood of patients with urological malignancies[J].Expert Rev Mol Diagn,2015,15(4):505-516.
7 Jia Y,Guo M.Epigenetic changes in colorectal cancer[J].Chin J Cancer,2013,32(1):21-30.
8 Kim H,D′Andrea AD.Regulation of DNA cross-link repair by the Fanconi anemia/BRCA pathway[J].Genes Dev,2012,26(13):1393-1408.
9 Grabbe C,Husnjak K,Dikic I.The spatial and temporal organization of ubiquitin networks[J].Nat Rev Mol Cell Biol,2011,12(5):295-307.
10 Jung JK,Jang SW,Kim JM.A novel role for the deubiquitinase USP1 in the control of centrosome duplication[J].Cell Cycle,2016,15(4):584-592.
11 Weber M,Hellmann I,Stadler MB,et al.Distribution,silencing potential and evolutionary impact of promoter DNA methylation in the human genome[J].Nat Genet,2007,39(4):457-466.
12 Falzone L,Salemi R,Travali S,et al.MMP-9 overexpression is associated with intragenic hypermethylation of MMP9 gene in melanoma[J].Aging(Albany NY),2016,8(5):933-944.
13 Singer M,Kosti I,Pachter L,et al.A diverse epigenetic landscape at human exons with implication for expression[J].Nucleic Acids Res,2015,43(7):3498-3508.
14 McMichael AJ.Food,nutrition,physical activity and cancer prevention.Authoritative report from World Cancer Research Fund provides global update[J].Public Health Nutr,2008,11(7):762-763.

[1]	普睿, 朱琳, 夏婷婷, 毕皓然, 孙鸿儒, 黄浩, 张磊, 赵亚双. 外周血STAT1,STAT3基因启动子CpG岛甲基化状态与大肠癌预后关系的研究[J]. 实用肿瘤学杂志, 2019, 33(4): 346-351.
[2]	吕强, 陈洪生, 李国东, 魏九峰(综述), 刘明(审校). 肿瘤相关成纤维细胞在大肠癌发生发展中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(3): 275-279.
[3]	段佩雯, 赵苗苗综述, 王松坡审校. NF-κB对大肠癌发生发展的影响及其相关治疗的研究现状[J]. 实用肿瘤学杂志, 2017, 31(1): 43-47.
[4]	吴杨佳子,鹿晓麟,赵琦,高玉艳,张艳桥. Arg-1在大肠炎症相关性肿瘤中的表达及意义[J]. 实用肿瘤学杂志, 2016, 30(4): 339-345.
[5]	王倩, 陈铁龙, 王彩芹, 罗微. 大肠癌中CD133、COX-2的表达及DNA倍体的研究[J]. 实用肿瘤学杂志, 2016, 30(3): 200-206.
[6]	张津宁, 李国东, 陈洪生综述, 刘明校审. 鞣花酸及其肠道代谢产物在大肠癌中的研究进展[J]. 实用肿瘤学杂志, 2016, 30(3): 262-265.
[7]	黄卫东, 于洪娟, 郑二维, 贺长志, 赵晓雯综述, 刘国祥校审. 大肠癌筛查经济学评价研究进展[J]. 实用肿瘤学杂志, 2015, 29(5): 462-466.
[8]	宫晨,周军德,迟强,崔滨滨,赵亚双,王帆. CYP24A1基因多态性与大肠癌发生及预后的关系[J]. 实用肿瘤学杂志, 2015, 29(4): 289-293.
[9]	刘晓娟,陈文杰,刘洪波,张锦明,张岩. 表观基因组研究揭示23个由DNA甲基化异常介导的乳腺癌致病基因的研究[J]. 实用肿瘤学杂志, 2015, 29(4): 299-304.
[10]	吕付龙,王泽涛,王劲松. RASSF1A及其甲基化与乳腺癌的关系[J]. 实用肿瘤学杂志, 2015, 29(4): 372-375.
[11]	尹惠子,单明,尤子龙(综述),庞达(审校). 肿瘤发生过程中表观遗传学机制-DNA甲基化的研究进展[J]. 实用肿瘤学杂志, 2015, 29(2): 173-177.
[12]	方东, 王志红. 中性粒细胞/淋巴细胞比值在大肠癌癌变进展中的指示价值[J]. 实用肿瘤学杂志, 2015, 29(1): 44-48.
[13]	崔滨滨, 刘彦龙, 陈洪生, 周飞, 于雪峰, 徐海涛. 抑癌基因ING3在大肠癌中表达及意义[J]. 实用肿瘤学杂志, 2014, 28(6): 481-484.
[14]	薛伟男,张干,杨艳梅,马玉彦,孙根,崔滨滨. 抑癌基因ING1在大肠癌中的表达及预后意义[J]. 实用肿瘤学杂志, 2014, 28(5): 385-390.
[15]	于歌综述, 王晶审校. 卵巢癌DNA甲基化的研究进展[J]. 实用肿瘤学杂志, 2013, 27(1): 81-84.